Meeting
2024 ASCO Annual Meeting
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.
Authors
Alireza Mansouri
Penn State Milton S. Hershey Medical Center, Hershey, PA
Alireza Mansouri , Debarati Bhanja , Hannah E. Wilding , Nicholas Mikolajewicz , Ahmad Ozair , Manmeet Singh Ahluwalia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2022)
DOI
10.1200/JCO.2024.42.16_suppl.2022
Abstract #
2022
Poster Bd #
321
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.
First Author: Clara Allayous
Poster
2020 ASCO Virtual Scientific Program
A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma.
First Author: Yuval Shaked
Poster
2020 ASCO Virtual Scientific Program
The use of plasma proteomic markers to understand the biology of immunotherapy response.
First Author: Arnav Mehta
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Venous thromboembolism (VTE) in melanoma patients (pts) on immunotherapy (IO).
First Author: Tamara A. Sussman